REVOLUTION MEDICINES INC

Revolution Medicines’ FDA approval of Rasonque sparks a rally, yet analysts warn the stock’s price may already include most upside. Despite unprofitability, its small‑molecule RAS/MAPK focus could reshape oncology if adoption and reimbursement follo…

Revolution Medicines pivots from pancreatic to lung cancer, aiming to unlock high‑growth oncology opportunities with its precision‑genomics platform.

Revolution Medicines’ Bloomberg 500 debut and FDA approval of Rasonque show a 48% survival lift in metastatic pancreatic cancer, boosting investor confidence and clinical adoption.

Revolution Medicines reports Q2 2026 earnings, nearly $4 B cash, and FDA NDA for daraxonrasib—offering a new RAS‑inhibitor option in metastatic pancreatic cancer.

Paradigm Biocapital’s stake boost in Jade Biosciences signals strong confidence in its precision oncology pipeline and partnership network, offering investors a rare glimpse into biopharma’s next‑generation therapeutic opportunities.

Revolution Medicines CEO sells option‑acquired shares amid a brokerage price‑target upgrade—insider liquidity, strong revenue growth, and strategic reimbursement plans reveal a biotech firm poised for long‑term growth.

Revolution Medicines CFO’s recent insider trades show routine portfolio moves, with a net 4% gain—no strategic shift, just standard 10(b)(5)(1) activity.

Revolution Medicines CFO’s June 24 trades reveal insider confidence and regulatory strategy, offering investors insight into the company’s governance and future outlook.

Revolution Medicines files a routine insider sale under Rule 144, but its oncology pipeline and FDA plans for RMX‑101 remain on track, offering a new lung‑cancer option.

Revolution Medicines’ 10‑b5‑1 sales show prudent tax‑liquidity handling while maintaining a strong pipeline, positive cash flow and a cost‑effective tech strategy that boosts payer appeal and patient access in oncology.